Literature DB >> 30782488

Poliovirus immunity among children under five years-old in accessible areas of Afghanistan, 2013.

Christopher H Hsu1, Kathleen A Wannemuehler2, Sajid Soofi3, Mohd Mashal4, Imtiaz Hussain3, Zulfiqar A Bhutta3, Larin McDuffie5, William Weldon6, Noha H Farag7.   

Abstract

BACKGROUND: Afghanistan remains among the three countries with endemic wild poliovirus transmission, and high population immunity levels are required to interrupt transmission and prevent outbreaks. Surveillance and vaccination of children in Afghanistan have been challenging due to security issues limiting accessibility in certain areas.
METHODS: A serosurvey was conducted in 2013 within accessible enumeration areas (EAs) among children aged <5 years using samples collected for a national micronutrient assessment survey to assess poliovirus immunity in Afghanistan. Of 21194 total EAs in Afghanistan, 107 were inaccessible and therefore were excluded from the sampling frame.
RESULTS: Population immunity was high overall but varied for the poliovirus serotypes, and was lowest for type 3 (95% [95% CI: 93%, 96%]) compared to type 1 (99% [95% CI:97%, 99%]) and type 2 (98% [95% CI:96%, 99%]). The proportion of the population immune to all three types was 93% (95% CI: 91%, 95%), and the proportion seronegative for all three types was 0.5% (95% CI: 0.2%, 1.7%).
CONCLUSION: Except for regional differences in immunity to type 3 virus, there were no other apparent differences in seroprevalence by region or by any of the demographic or nutritional characteristics assessed in this study. The study was not powered to provide provincial level seroprevalence estimates, but Paktika Province, in the South region, had the largest proportion of seronegative specimens for type 1 (4 seronegative of 17 serum specimens compared to 14 seronegative of 673 for the remainder of the areas). Among accessible children in Afghanistan, seroprevalence of antibodies to poliovirus was high, with most seroprevalence reported at 95% or greater. Despite high seroprevalence in areas assessed in this study, the continued detection of poliovirus cases in the South and East regions indicate that overall regional vaccination coverage and performance is not sufficient to stop polio transmission. Published by Elsevier Ltd.

Entities:  

Keywords:  Afghanistan; Eradication; Immunity; Poliovirus; Serosurvey

Mesh:

Substances:

Year:  2019        PMID: 30782488      PMCID: PMC6466626          DOI: 10.1016/j.vaccine.2019.02.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Progress Toward Poliomyelitis Eradication--Pakistan, January 2014-September 2015.

Authors:  Noha H Farag; Mufti Zubair Wadood; Rana Muhammad Safdar; Nabil Ahmed; Sabrine Hamdi; Rudolph H Tangermann; Derek Ehrhardt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-11-20       Impact factor: 17.586

2.  Progress Toward Poliomyelitis Eradication - Pakistan, January 2015-September 2016.

Authors:  Christopher H Hsu; Abdirahman Mahamud; Rana Muhammad Safdar; Jamal Ahmed; Jaume Jorba; Salmaan Sharif; Noha Farag; Maureen Martinez; Rudolph H Tangermann; Derek Ehrhardt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-25       Impact factor: 17.586

3.  Progress Toward Poliomyelitis Eradication - Afghanistan, January 2015‒August 2016.

Authors:  Chukwuma Mbaeyi; Hemant Shukla; Philip Smith; Rudolf H Tangermann; Maureen Martinez; Jaume C Jorba; Stephen Hadler; Derek Ehrhardt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-04       Impact factor: 17.586

4.  Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.

Authors:  Andrew Etsano; Eunice Damisa; Faisal Shuaib; Gatei Wa Nganda; Ogu Enemaku; Samuel Usman; Adekunle Adeniji; Jaume Jorba; Jane Iber; Chima Ohuabunwo; Chimeremma Nnadi; Eric Wiesen
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-08-05       Impact factor: 17.586

5.  Implications of a circulating vaccine-derived poliovirus in Nigeria.

Authors:  Helen E Jenkins; R Bruce Aylward; Alex Gasasira; Christl A Donnelly; Michael Mwanza; Jukka Corander; Sandra Garnier; Claire Chauvin; Emmanuel Abanida; Muhammad Ali Pate; Festus Adu; Marycelin Baba; Nicholas C Grassly
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Standardized Methods for Detection of Poliovirus Antibodies.

Authors:  William C Weldon; M Steven Oberste; Mark A Pallansch
Journal:  Methods Mol Biol       Date:  2016

7.  The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.

Authors:  Kathleen M O'Reilly; Elias Durry; Obaid ul Islam; Arshad Quddus; Ni'ma Abid; Tahir P Mir; Rudi H Tangermann; R Bruce Aylward; Nicholas C Grassly
Journal:  Lancet       Date:  2012-07-04       Impact factor: 79.321

8.  Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population.

Authors:  Steven Wassilak; Muhammad Ali Pate; Kathleen Wannemuehler; Julie Jenks; Cara Burns; Paul Chenoweth; Emmanuel Ade Abanida; Festus Adu; Marycelin Baba; Alex Gasasira; Jane Iber; Pascal Mkanda; A J Williams; Jing Shaw; Mark Pallansch; Olen Kew
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

9.  Seroprevalence of Poliovirus Antibodies in the United States Population, 2009-2010.

Authors:  Gregory S Wallace; Aaron T Curns; William C Weldon; M Steven Oberste
Journal:  BMC Public Health       Date:  2016-08-05       Impact factor: 3.295

10.  Progress toward poliomyelitis eradication--Afghanistan and Pakistan, January 2013-August 2014.

Authors:  Noha H Farag; James Alexander; Stephen Hadler; Arshad Quddus; Elias Durry; Mufty Zubair Wadood; Rudolph H Tangermann; Derek Ehrhardt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-10-31       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.